Sagimet Biosciences Says Phase 2B FASCINATE-2 Trial Results Of Denifanstat Versus Placebo In Metabolic-dysfunction Associated Steatohepatitis Patients With Stage 2 Or Stage 3 Fibrosis Were Published In The Lancet Gastroenterology & Hepatology
Portfolio Pulse from Benzinga Newsdesk
Sagimet Biosciences announced positive Phase 2B trial results for denifanstat in treating metabolic-dysfunction associated steatohepatitis (MASH) with significant improvements in disease activity and fibrosis. The results support moving to Phase 3 trials.
October 11, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sagimet Biosciences' Phase 2B trial results for denifanstat showed significant improvements in MASH treatment, supporting advancement to Phase 3 trials.
The positive Phase 2B trial results for denifanstat indicate significant clinical benefits, which is likely to boost investor confidence and positively impact Sagimet Biosciences' stock price as the drug progresses to Phase 3 trials.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100